Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Clearmind Medicine Inc (NQ: CMND ) 1.230 +0.120 (+10.81%) Streaming Delayed Price Updated: 3:59 PM EDT, Jun 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 365,228 Open 1.130 Bid (Size) 1.210 (1) Ask (Size) 1.270 (19) Prev. Close 1.110 Today's Range 1.110 - 1.270 52wk Range 0.1000 - 6.800 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024 June 17, 2024 Clearmind Medicine just reported results for the second quarter of 2024. Via InvestorPlace What's Going On With Clearmind Medicine Stock Tuesday? June 11, 2024 Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Performance YTD -55.76% -55.76% 1 Month +2.50% +2.50% 3 Month -4.65% -4.65% 6 Month -55.27% -55.27% 1 Year +135.90% +135.90% More News Read More Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink June 11, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product May 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 07, 2024 Via Benzinga Why Clearmind Medicine Stock Is Moving Higher May 07, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment May 07, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Applies to Cease Being a Reporting Issuer in Canada April 30, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More April 17, 2024 Via Benzinga Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders April 17, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders April 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine CEO Issues Letter to Shareholders April 09, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More March 30, 2024 Via Benzinga Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence March 29, 2024 Via Benzinga Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression March 27, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More March 20, 2024 Via Benzinga Topics Economy Exposures Interest Rates Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket March 20, 2024 Via Benzinga Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China March 19, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review March 16, 2024 Via Benzinga Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial March 13, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange March 13, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors March 12, 2024 Via Benzinga Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More March 04, 2024 Via Benzinga SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds February 27, 2024 From SciSparc Ltd Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
